Literature DB >> 10892386

Age-related seroprevalence of Cryptosporidium in northern Israel.

D Miron1, R Colodner, Y Kenes.   

Abstract

BACKGROUND: Two recent studies found that the prevalence of cryptosporidiosis among children in Israel was 3.4-7.4%.
OBJECTIVES: To assess the cumulative infection rate by testing immunoglobulin A and G seroprevalence for Cryptosporidium in children and adults in Israel. PATIENTS AND METHODS: The seroprevalence of IgA and IgG anti-Cryptosporidium antibodies was determined by an enzyme-linked immunosorbent assay procedure in a group of 163 healthy children and adults.
RESULTS: The overall seroprevalence rates for IgG, IgA, both IgA and IgG, and any immunoglobulin were 12.6%, 23%, 30% and 65.6% respectively. Half the children under the age of 12 years were already infected, with seroprevalence increasing to 95.6% in those over age 13 (P < 0.05). Seropositivity for IgG or IgA did not significantly increase with age.
CONCLUSIONS: These results indicate that a large percentage of healthy children and adults in northern Israel have been infected with Cryptosporidium, and at early ages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10892386

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  3 in total

1.  Serological responses to Cryptosporidium infection.

Authors:  T B Muller; F J Frost; G F Craun; R L Calderon
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Serum IgG responses and seroconversion patterns to Cryptosporidium gp15 among children in a birth cohort in south India.

Authors:  Rajiv Sarkar; Sitara Swarna Rao Ajjampur; Jayaprakash Muliyil; Honorine Ward; Elena N Naumova; Gagandeep Kang
Journal:  Clin Vaccine Immunol       Date:  2012-04-18

3.  Molecular typing of Cryptosporidium in Israel.

Authors:  Tamar Grossman; Shifra Ken-Dror; Elsa Pavlotzky; Julia Vainer; Yael Glazer; Orli Sagi; Avi Peretz; Vered Agmon; Esther Marva; Lea Valinsky
Journal:  PLoS One       Date:  2019-09-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.